Product Description
The more you know about your psoriasis, the better you can deal with it. This invaluable guide gives you medically accurate, practical information on the day-to-day management of the condition. Psoriasis at your fingertips answers over 200 real questions from people with psoriasis and their families. The expertauthors pass on useful, easy-to-follow advice on living with psoriasis. They discuss the various treatments available,helping you to discover which work best for you, and give you effective self-help routines.Psoriasis at your fingertipsoffers up-to-date, positive and practical help, covers topics such as work, holidays, relationships and other people's attitudes, answers the questions your doctor may not have time to answer, and makes it clear that you are not alone. ... Read more

Product Description
This digital document is an article from Dermatology Nursing, published by Jannetti Publications, Inc. on December 1, 2008. The length of the article is 644 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

From the author: Dermatology nurses and other health care professionals may sometimes fail to appreciate and recognize the physical and emotional challenges faced by patients with a particular chronic dermatologic disease or condition. "Patients' Perspectives: Living with ... " series shares these important patient views and comments to improve patient care. If you know of a patient who would be interested in sharing his/her experiences with the dermatology nursing community, please ask him/her to briefly answer (3-5 sentences) the questions as outlined here. Submissions can be sent via e-mail to the journal office at dnjrnl@ajj.com or mailed to Patients' Perspectives, Dermatology Nursing, East Holly Avenue Box 56, Pitman, NJ 08071-0056.

Citation Details
Title: Living with psoriasis.(Patient's Perspectives)
Author: Linda Cornish
Publication: Dermatology Nursing (Magazine/Journal)
Date: December 1, 2008
Publisher: Jannetti Publications, Inc.
Volume: 20Issue: 6Page: 478(2)

Distributed by Gale, a part of Cengage Learning ... Read more

Product Description
This econometric study covers the latent demand outlook for psoriasis drugs across the states, union territories and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 5,000 cities in India. For each city in question, the percent share the city is of it's state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-a-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state or union territory and city, latent demand estimates are created for psoriasis drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in India). This study gives, however, my estimates for the latent demand, or the P.I.E., for psoriasis drugs in India. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of India. For each state or union territory, I also show my estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business. ... Read more

Product Description
This econometric study covers the latent demand outlook for psoriasis drugs across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in Greater China. For each major city in question, the percent share the city is of the region and of Greater China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits; this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-a-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for psoriasis drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products ... Read more

Product Description
This econometric study covers the outlook for psoriasis drugs in Europe. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries in Europe). This study gives, however, my estimates for the latent demand, or the P.I.E. for psoriasis drugs in Europe. It also shows how the P.I.E. is divided across the national markets of Europe. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business. ... Read more

Product Description
This is an OCR edition without illustrations or index. It may have numerous typos or missing text. However, purchasers can download a free scanned copy of the original rare book from GeneralBooksClub.com. You can also preview excerpts from the book there. Purchasers are also entitled to a free trial membership in the General Books Club where they can select from more than a million books without charge. Original Published by: J. & A. Churchill in 1875 in 253 pages; Description: Bound in: Selection from J. & A. Churchill's general catalogue on the science of medicine, l6 p., October, 1887.; Subjects: LawPsoriasis; Law / General; Law / Administrative Law & Regulatory Practice; Law / Civil Procedure; Law / Constitutional; Law / International; Law / Reference; Literary Collections / Essays; Medical / Dermatology; Travel / Essays & Travelogues; ... Read more

Product Description
Northwestern Univ., Chicago, IL. Key reference for the practicing physician treating patients with this disease. Halftone and color plates and photographs. Volume expected to be updated every five years. Previous edition date not listed. ... Read more

Product Description
Psoriasis is a skin condition affecting some two per cent of the population, and occurs when the skin cells replace themselves too quickly. There are many different types, but the most common is chronic plaque psoriasis. The cause is unknown, but triggers are thought to include skin injury, sore throat or chest infections, certain drug treatments, sunburn and stress. A specific form of arthritis is related to psoriasis. Psoriasis usually appears as red, scaly patches that reveal fine silvery scales when scraped or scratched. These patches may itch and feel uncomfortable. It's most common on the knees, elbows and scalp, but can appear anywhere on the body.Some people with psoriasis become withdrawn and don't socialise or form relationships because of the way people react to the appearance of their skin. Treatment and self-help can however be effective, as this book shows.Topics include: Psoriasis and your health (arthritis; more rarely, other complications such as circulation and bowel problems); Treatments such as emollients, skin softeners and topical drug therapy applied to the skin, such as vitamin D derivatives, tar preparations, steroids, dithranol preparations and vitamin A derivatives; Ultraviolet B light therapy, systemic medication (methotrexate, ciclosporin, aitretin, hydroxycarbamide), and biologics designed to block specific molecules in the immune system that trigger development of psoriasis (etanercept, infliximab, efalizumab); Complementary therapies such as acupuncture, homeopathy and herbal therapy; Psoriasis in children; guttate psoriasis (a type common in children after a respiratory infection); and, Emotions and confidence. ... Read more

Product Description
Heal YOUR Psoriasis And Look Great is dedicated to the millions of people worldwide suffering from psoriasis. This groundbreaking book teaches you how to strengthen your immune system, clear your skin, look great, and become healthy. Your holistic solution is based entirely on your genetics, and lifestyle choices. Learn what doctors, drug companies, and insurance companies are not telling you about healing psoriasis. "One who understands others has knowledge. One who understands himself has wisdom." - the Tao ... Read more

Product Description
This econometric study covers the outlook for psoriasis drugs in the Middle East. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries in the Middle East). This study gives, however, my estimates for the latent demand, or the P.I.E. for psoriasis drugs in the Middle East. It also shows how the P.I.E. is divided across the national markets of the Middle East. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business. ... Read more

Product Description
A study on the aetiology and treatment of psoriasis and eczema. ... Read more

Product Description
This econometric study covers the latent demand outlook for psoriasis drugs across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,900 cities in the United States. For each city in question, the percent share the city is of it's state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-a-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for psoriasis drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in the United States). This study gives, however, my estimates for the latent demand, or the P.I.E., for psoriasis drugs in the United States. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of the United States. For each state, I also show my estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business. ... Read more

Product Description
From Arsenic to Biologicals: A 200 year History of Psoriasis is a chronological description of how the unravelling of the mechanisms underlying psoriasis have led to a change from the empirical "try it and see" treatments of the 19th and early 20th centuries to the evidence-based treatments of the present day.The book explains the various theories proposed to explain psoriasis and describes the introduction of new treatments, decade by decade, throughout the 20th century.These range from the belief that psoriasis resulted from an internal metabolic disturbance in the 19th century, when arsenic was the systemic treatment of choice, through to the 21st century when the recognition that psoriasis is a disease of the immune system enabled the development and use of therapeutic biological agents. ... Read more

Customer Reviews (1)

A unique resource for people with an interest in psoriasis
This book provides a thorough and useful survey of the history of our understanding of psoriasis and its treatment, spanning mainly the last two centuries.The writing is clear and the ~120 pages don't take too long to read, although the technical level is moderately high, so the book is targeted mainly at professionals.

A couple of quirky aspects are that the author's credentials aren't stated (though she appears to be a qualified researcher) and, more significantly, the book doesn't have an index.

The following are some interesting and/or important points from the book:

- The presence of increased vascularization (with increased capillary tortuosity and permeability) and leukocytes in psoriatic lesions was identified more than a century ago.Later studies revealed the presence of epidermal hyperproliferation driven by an external stimulus, inadequate epidermal differentiation, and identification of T cells (particularly Th1 CD4+ cells) as the primary leukocytes involved.

- Psoriasis hasn't been observed in non-human animals, which limits the usefulness of animal models.

- There are a wide variety of treatments for psoriasis, with diverse mechanisms of action.No treatment works for everyone, no treatment is curative, and treatments often eventually lose efficacy.Spontaneous remission of psoriasis is also sometimes observed.

- The earlier psoriasis treatments were discovered mainly by trial and error, yet many are still in use decades after their discovery.

- Some of the early psoriasis treatments, such as arsenic, mercury, and X-rays, were highly toxic.Some of the treatments still in use today, such as methotrexate and hydroxyurea (both of which are cancer drugs), are also quite toxic at higher doses.

- Corticosteroids were among the first psoriasis treatments with reasonably well understood mechanisms of action.Slight modifications in the molecular structure of these steroids can greatly change their potency.

- More than 80% of patients who have tried Dead Sea bathing have seen complete or nearly complete clearing of their psoriasis (but not permanently), and many have also seen improvement in their arthritis.

- Phototherapy (a type of radiotherapy) and photochemotherapy (phototherapy typically combined with a photosensitizer) have been found effective against psoriasis, although they carry some carcinogenic risk.

- Cold weather, stress, poor diet, and skin trauma are known to contribute to psoriasis.

- Microbes appear to contribute to triggering or exacerbating psoriasis in some patients.

- Some drugs used for other conditions, such as chloroquine, lithium, beta-blockers, and indomethacin (a COX inhibitor), can trigger or exacerbate psoriasis.

- A genetic contribution to psoriasis became clearly evident many decades ago.Later studies showed that psoriasis is polygenic, which is part of the reason for the clinical heterogeneity of psoriasis.Some of the genes linked with psoriasis also appear to be linked with inflammatory and autoimmune diseases such as atopic dermatitis, Crohn's disease, rheumatoid arthritis, and lupus.

- Cytokines appear to play a large role in driving psoriasis.TNF-alpha is an unusual cytokine because it inhibits keratinocyte proliferation, but it also indirectly contributes to epidermal growth by inducing IL-8 and TGF-alpha production, with the net result that inhibiting TNF-alpha clinically improves psoriasis.

- The key role of the immune system in psoriasis, particularly modulation by T cells, is evidenced by the clinical efficacy of broadly immunosuppressive agents (eg, cyclosporin and tacrolimus) as well as targeted immunotherapies ("biologics").Data on the long-term safety of targeted immunotherapies (most of which target TNF-alpha) isn't yet available.

- Antigens are hypothesized to drive psoriasis, but specific antigens haven't been identified, and thus it's not yet known whether psoriasis is an autoimmune disease involving self-antigens (though many people suspect this).

- Gene therapies (anti-sense RNAs) for psoriasis are under development.In addition, pharmocogenomics may eventually enable individualized treatment of psoriasis.

One feature of psoriasis not mentioned in this book, and infrequently mentioned in the broader literature, is the high level of bilateral symmetry of psoriasis.It seems to me that this is a very striking and important pathophysiologic clue which researchers have neglected to adequately investigate.

Overall, I think this book is a must-read for psoriasis researchers and clinicians, and patients and caregivers with a good grasp of biomedicine may also find the book beneficial. ... Read more